Veröffentlichungsdatum: 11 März 2019
Projektträger – zwischengeschaltetes Finanzinstitut
The project consists of the financing of Mobidiag, an innovative medtech company based in Finland. This financing will help Mobidiag to develop new diagnostic tests for infectious diseases.
The proposed transaction will support research and development (R&D) investments that are required in order to further advance the promoter's product pipeline and bring the products to market.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 25 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 66 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 14/05/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).